Fulcrum Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FULC Nasdaq 2836 www.fulcrumtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 9th, 2026 2:30 pm
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Jan 7th, 2026 6:00 am
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet - Dec 30th, 2025 7:55 am
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study - Dec 21st, 2025 5:31 am
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - Dec 10th, 2025 5:48 am
Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data - Dec 9th, 2025 1:09 am
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - Dec 8th, 2025 2:01 pm
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - Dec 6th, 2025 3:30 pm
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 - Dec 2nd, 2025 6:30 am
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - Nov 20th, 2025 10:33 am
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - Nov 19th, 2025 2:20 pm
Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls - Nov 6th, 2025 7:45 am
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - Nov 3rd, 2025 2:45 pm
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 - Oct 29th, 2025 5:00 am
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET - Oct 22nd, 2025 6:54 am
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 - Oct 14th, 2025 5:00 am
Here's Why We're Not Too Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation - Sep 17th, 2025 8:15 am
Fulcrum Therapeutics to Present at Upcoming Investor Meetings - Aug 26th, 2025 6:00 am
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - Jul 29th, 2025 4:48 am
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - Jul 29th, 2025 4:45 am